Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus - Test2 - elhamkhani - TriplyDB

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

http://www.wikidata.org/entity/Q26774021

about

Type 2 diabetes and quality of life.Postprandial and Orthostatic Hypotension Treated by Sitagliptin in a Patient with Dementia with Lewy Bodies.Management of Adults With Diabetes and Cognitive Problems Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose.Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.

P2860

Q33573159-37205C43-F5B8-48B9-A818-116E84E7E05B Q37452044-7CF9F65F-6BF1-4128-9EAA-FCCBE37A88F4 Q42748390-1791A67B-A58C-4177-8449-BC31A006D4B2 Q47555696-D2B4CF7F-D328-4A06-9672-D1A768585796 Q49414493-DF6F7500-C742-49B2-9E1A-2835D16F30BB Q50348623-D0A09F87-FDA6-41E6-8DA2-F42C2D25A802

P2860

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

http://www.wikidata.org/entity/Q26774021

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@ast

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@en

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@nl

type

label

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@ast

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@en

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@nl

prefLabel

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@ast

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@en

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@nl

P1433

Q26774021-5A6B9A22-057C-4F5B-AA10-C6742CB36D1A

P1476

Q26774021-F797947E-4824-4658-85E8-BCC28FDCF332

P2093

Q26774021-57D80463-B7E9-420D-8103-28051FE3E07E

Q26774021-604BE675-49B9-4C4E-A240-8617164B98AD

Q26774021-BA4FE09B-E4CA-4E70-9F5F-AED03A687E9E

P275

Q26774021-EF0DE2F6-A2E8-45C6-B521-DA768CDDF7C0

P2860

Q26774021-0030A8EC-5AA3-49A2-A22A-72EE049D64F1

Q26774021-01710328-9368-4A74-BBE4-DFA7F590FBEE

Q26774021-087B3627-BB3B-463B-AA46-6B6DC2485D8A

Q26774021-08C89DDD-9212-4329-B3B1-1E697A15AD38

Q26774021-08F6984C-0611-46D5-A09A-97EA7CD7F58D

Q26774021-0A25CE06-3141-481F-80DC-CFE6637C7028

Q26774021-10C8DFBC-E0E7-4E85-9ADA-A44A9F94E586

Q26774021-178AE872-253F-4305-97C7-A8CD0E96B95D

Q26774021-1B68166F-2451-4D02-9F8D-53F48A8111BD

Q26774021-1BFF0648-E5D6-4DE7-A555-8811B19281FE

P304

Q26774021-12C32AA1-8915-4804-8CE0-58FBD177ADAE

P31

Q26774021-56BDBB26-675C-4F1B-944A-D94ECA102E51

Q26774021-F645DBA5-50AA-41D8-AE01-358F3EC72F73

P356

Q26774021-C64BE0F6-A7A8-487B-AAC1-5C85A3FFCF0A

P407

Q26774021-A87BB6FA-5F6C-4AB7-8CA7-5253BB79B704

P433

Q26774021-FEC86335-0106-45CA-9198-359BBD8C4EA8

P478

Q26774021-D64757FE-3B15-4BB1-85AF-A4EE25E0209B

P5008

Q26774021-963AC727-E376-4EC2-8119-399ADC3D4A07

P577

Q26774021-413D6661-44ED-4179-BA76-94490DF4EE57

Q26774021-D43BB5DA-E104-42E3-B76F-FD94EDCC80F3

P698

Q26774021-37BA3181-B386-432F-ACA2-F02CA7DE25ED

P921

Q26774021-41550577-A048-44B0-A324-ACC1C1D0EED8

Q26774021-4B4D1B9D-6370-4A3B-9FAD-0ED83B75DBA3

Q26774021-681A6C11-F81A-4DE9-A6C4-6192BE914F67

Q26774021-6BA1FB95-DC89-455B-9CD5-DF18BCE75D95

Q26774021-CA0F7E00-BDC8-49DE-A01B-580A53BCAD84

Q26774021-EE3C43A9-CC57-4836-825C-5FBE1256C377

Q26774021-F62FE132-A062-4A7C-AB22-673DD5546682

P932

Q26774021-C1542CFA-99E6-409F-BC0F-B073FEBF7FEB

P356

P1433

Journal of Diabetes Investigation

P1476

Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus

@en

P2093

Geert Jan Biessels

http://www.w3.org/2001/XMLSchema#string

L Jaap Kappelle

http://www.w3.org/2001/XMLSchema#string

Onno N Groeneveld

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Insulin for glycaemic control in acute ischaemic stroke

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus

Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Neuroinflammation in Alzheimer's disease

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

P304

5-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDI.12420

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26816596

http://www.w3.org/2001/XMLSchema#string

P921

cerebrovascular disease

type-2 diabetes

mechanism of action

maturity-onset diabetes of the young

P932

4718099

http://www.w3.org/2001/XMLSchema#string